A new microfluidic device containing human cells that faithfully mimics the behavior of the blood-brain barrier is providing new insights into brain inflammation, the silent killer.

Vanderbilt researchers have established a new measure of resilience to cognitive impairment in people with asymptomatic Alzheimer’s disease.

Understanding how mutations affect the structure and function of inhibitory neurotransmitter receptors will shed light on the mechanisms underlying some types of epilepsy.

Vanderbilt researchers have identified cocaine-induced modifications at specific neuronal connections, which could aid the development of new therapies for substance abuse disorders.

Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice.

A consortium led by Vanderbilt University Medical Center (VUMC) researchers has received funding as it makes plans for a multicenter trial that could determine whether deep brain stimulation (DBS) slows the progression of Parkinson’s disease in early-stage patients.

Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.